线性超滤模式联合左卡尼汀对维持性血液透析低血压的疗效观察  被引量:2

The efficacy observation of linear ultrafiltration mode combined with levocarnitine on maintenancehemodialysis hypotension

在线阅读下载全文

作  者:胡兆雄[1] 吴小燕[2] 肖厚勤[1] 郑璇[1] 

机构地区:[1]湖北医药学院附属十堰市太和医院肾内科,湖北十堰442000 [2]武汉大学中南医院肾内科,湖北武汉430030

出  处:《四川医学》2013年第3期399-401,共3页Sichuan Medical Journal

摘  要:目的探讨线性超滤模式联合左卡尼汀对维持性血液透析低血压的疗效。方法将本院收治的64例维持性血液透析患者随机分为对照组和观察组,两组均在线性超滤模式下透析,仅观察组加用左卡尼汀。分析两组治疗前、治疗1、6个月的血压指标(透析前血压和透析中的最低血压)并记录低血压和不良反应的发生率。结果治疗1个月后,观察组的最低血压高于治疗前,低血压及不良反应率均低于治疗前;治疗6个月后,两组的以上指标均优于治疗前,差异有统计学意义。观察组治疗1、6个月的透析中最低血压均高于对照组,除治疗6个月的收缩压(P<0.01),治疗1个月后的不良反应发生率低于对照组(P<0.05)。结论线性超滤模式联合左卡尼汀对维持性血液透析低血压的治疗和预防效果均较好,不仅提高透析中最低血压,而且还可降低低血压及不良反应发生率。Objective To explore the effecacy of linear ultrafiltration mode combined with levocarnitine on maintenance hemodialysis hypotension. Methods 64 patients on maintenance hemodialysis admitted by our hospital from January to December 2011 were randomly divided into control group and observation group. Both groups underwent dialysis under linear uhrafihration mode, and only the observation group was given levocarnitine additionally. The iollowing indices were compared between two groups, such as blood pressure parameters( predialysis blood pressure and dialysis hypotension)and rate of hypotension and ad- verse reaction. Results The dialysis hypotension values in observation group of 1 st and 6th month post-treatment were higher than those of Control group, and despite the systolic blood pressure of 6th month post-treatment (P 〈 0. 01 ), the rest were P 〈 0. 05. The rates of hypotension in observation group was lower than Control group as well as the adverse reaction 1st month post-treatment ( P 〈 0. 05 ). Conclusion The effecacy of linear uhrafiltration mode combined with levocarnitine on maintenance hemodialysis hy- potension is better.

关 键 词:线性超滤模式 左卡尼汀 维持性血液透析低血压 疗效 

分 类 号:R459.5[医药卫生—治疗学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象